Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:dosage_form |
gptkb:Software_Solutions
|
| gptkbp:effective_date |
2018-08-03
|
| https://www.w3.org/2000/01/rdf-schema#label |
Takhzyro
|
| gptkbp:indication |
prevention of angioedema attacks
|
| gptkbp:ingredients |
gptkb:lanadelumab
|
| gptkbp:manufacturer |
gptkb:Shire_Pharmaceuticals
|
| gptkbp:marketed_as |
gptkb:Takhzyro
|
| gptkbp:route_of_administration |
subcutaneous injection
|
| gptkbp:used_for |
treatment of hereditary angioedema
|
| gptkbp:bfsParent |
gptkb:Shire_plc
|
| gptkbp:bfsLayer |
5
|